Objectives: To study the effects of two different mixtures of the main conjugated linoleic acid (CLA) isomers cis-9, trans-11 CLA and trans-10, cis-12 CLA on human immune function. Design: Double-blind, randomized, parallel, reference-controlled intervention study. Subjects and intervention: Seventy-one healthy males aged 31 -69 y received one of the following treatments: (1) mixture of 50% c9,t11 CLA and 50% t10,c12 CLA isomers (CLA 50:50); (2) mixture of 80% c9,t11 CLA and 20% t10,c12 CLA isomers (CLA 80:20); and (3) sunflower oil fatty acids (reference). The treatments were given as supplements in softgel capsules providing a total of 1.7 g (c9,t11 þ t10,c12) CLA fatty acids (50:50) or 1.6 g (c9,t11 þ t10,c12) CLA glycerides (80:20) per day in treatment groups for 12 weeks. Results: Almost twice as many subjects reached protective antibody levels to hepatitis B when consuming CLA50:50 fatty acids (15=24, 62%) compared with subjects consuming the reference substance (7=21, 33%, P ¼ 0.075). In subjects consuming CLA 80:20 glycerides this was 8=22 (36%). Other aspects of immune function, ie DTH responses, NK cell activity, lymphocyte proliferation and production of TNF-a, IL1-b, IL6, IFN-g, IL2, IL4, and PGE 2 , were not affected.
Introduction
Conjugated linoleic acid (CLA) refers to a class of positional and geometric conjugated dienoic isomers of linoleic acid, of which cis-9, trans-11 (c9,t11) CLA and trans-10, cis-12 (t10,c12) CLA are the main isomers. CLA is naturally present in milk and meat of ruminants due to its production by anaerobic bacteria in the rumen of these animals and can be produced industrially by partial hydrogenation of linoleic acid (Chin et al, 1994; Parodi, 1994) . CLA concentrations in ruminant-derived products range from 3 to 7 mg CLA=g fat depending on source and processing of products (Chin et al, 1994; Lin et al, 1995; Shantha et al, 1993 Shantha et al, , 1995 . Estimated average daily intake of CLA from these dietary sources ranges from 0.19 to 1.5 g of CLA (Fritsche et al, 1998; Fritsche & Steinhart, 1998a) and varies for different countries (Parodi, 1994) . In Germany average intake of CLA is estimated as 350 mg for women and 430 mg per day for men (Fritsche & Steinhart, 1998b) . Unpublished data (TNO, Unilever) indicate that average intake for the Netherlands is about 200 -400 mg CLA per day.
Various positive health effects have been ascribed to CLA consumption, including anticarcinogenic (Ip et al, 1994 Thompson et al, 1997) , antiatherogenic (Lee et al, 1994; Nicolosi et al, 1997) , and antidiabetic activity (Houseknecht et al, 1998) . CLA has also been reported to decrease body fat while increasing lean body mass (Blankson et al, 2000; Delany et al, 1999; West et al, 1998) . In addition, animal studies have suggested that CLA has favorable effects on certain aspects of immune function (Hayek et al, 1999; Turek et al, 1998; Wong et al, 1997; Yang et al, 2000) , while ameliorating immunemediated catabolism (Cook et al, 1993; Miller et al, 1994) . Most of these physiological effects of CLA have been observed after feeding animals with mixtures of CLA isomers that contain mostly c9,t11 CLA and t10,c12 CLA in roughly equal amounts. These mixtures have been found to reduce endotoxin-induced wasting and enhance ex vivo lymphocyte proliferation in broilers (Cook et al, 1993; Miller et al, 1994) and decrease TNF-a and IL6 production in rats (Turek et al, 1998) . In mice, ex vivo lymphocyte proliferation (Miller et al, 1994) and IL2 production tended to be increased (Hayek et al, 1999) and cellular immunity was enhanced in pigs by modulating phenotype and effector functions of CD8 þ lymphocytes (Bassaganya-Riera et al, 2001a,b) . However, evidence for beneficial effects of CLA on immune function in humans is currently lacking (Kelley et al, 2000) .
Recently, evidence has been accumulating that different CLA isomers may have different health effects . In particular, c9,t11 CLA enhances growth and possibly feed efficiency in pigs , whereas t10,c12 CLA but not c9,t11 CLA has been found to affect body composition in mice (Park et al, 1999) and blood lipids in hamsters (de Deckere et al, 1999) . In vitro, selective activity of t10,c12 CLA has been reported for lipoprotein lipase (Lin et al, 2001 ) and stearyl CoA desaturase activity in adipocytes (Choi et al, 2000; Park et al, 2000) and for antioxidant activity (Leung & Liu, 2000) .
The present double blind, randomized, parallel, referencecontrolled trial was designed to determine (i) whether supplementation with a mixture of CLA isomers similar to those found to affect immune function in animals also affects immune function in humans and (ii) assess whether the two main isomers c9,t11 CLA and t10,c12 CLA differ in this respect. To this end, healthy immuno-competent men aged 31 -69 were supplemented for 12 weeks with different mixtures of these CLA isomers. Effects on immune function were measured, covering aspects of innate immunity (Natural Killer (NK) cell activity and monocyte function), primary adaptive immunity (antibody production and lymphocyte proliferation in response to a model infection mimicked by hepatitis B vaccination), memory adaptive immunity (delayed-type hypersensitivity (DTH) responses), and mitogen-induced proliferation and cytokine production.
Subjects and methods
Subjects and study design This study was conducted by TNO Nutrition and Food Research from September 1999 until May 2000, after approval by the TNO Medical Ethics Committee. The study was run in three cohorts, each comprising similar numbers of subjects per treatment group. Respondents to advertisements and flyers received written information and were invited to an oral briefing. At these meetings, about 130 volunteers signed an informed consent and were subsequently invited for physical and clinical examination. Based on in-and exclusion criteria, 81 volunteers were selected. Subjects were healthy, non-smoking, Caucasian males of 31 -69 y of age, with average Dutch dietary habits, BMI < 33 kg=m 2 , fasting serum cholesterol 7.5 mmol=l, { and without known diseases, use of medication or dietary supplements that may affect the immune system. They had normal blood chemistry (alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, g-glutamyltransferase, triacylglycerols, total bilirubin, urea, creatinin, C-reactive protein, albumin, prealbumin, a1-glycoprotein and glucose) and their antibody titers to hepatitis B were 4 IU=l at inclusion. Subjects were randomly allocated to one of the three treatment groups. Allocation was stratified for age, body mass index (BMI) and fasting serum cholesterol concentrations. Six subjects did not start the study and four dropped out during the study for reasons unrelated to the intervention. Seventy-one subjects completed the study, four subjects were previously vaccinated and were therefore excluded from the hepatitis B analysis; 10 subjects were excluded from the analysis of the DTH because of incomplete data sets.
The design of the study is outlined in Figure 1 . Subjects were asked to maintain their normal dietary habits and physical activity. They received one of the following treatments: (1) mixture of 50% c9,t11 CLA and 50% t10,c12 CLA fatty acids (CLA 50:50, Clarinol TM , Loders Croklaan, Figure 1 Study design. Subjects consumed two capsules with each meal (three times daily) from study day 3 to day 87. Subjects were vaccinated to hepatitis B on days 43, 57 and 71, and specific antibody concentrations were measured pre-study and at day 71 and 85. Delayedtype hypersensitivity tests (DTH) were applied at day 1 and 85. At these days blood was also drawn for assessment of CLA in PBMC, ex vivo immune function parameters and acute phase proteins.
{ When total cholesterol was > 7.5 mmol=l the ratio of total=HDL cholesterol was evaluated according to the standards of the 'Nederlands Huisartsen Genootschap'. Subjects at risk according to those standards were excluded.
CLA and immune function in man R Albers et al Netherlands); (2) mixture of 80% c9,t11 CLA and 20% t10,c12 CLA glycerides (CLA 80:20, Loders Croklaan, Netherlands); (3) sunflower oil fatty acids (reference). The fatty acid profile of the three supplements is given in Table 1 . The CLA 80:20 mixture consisted of glycerides as it was prepared by selective enzymatic esterification from CLA 50:50 fatty acids. CLA 50:50 in its turn was prepared from sunflower oil fatty acids, which was therefore used as reference. We used these mixtures of isomers because single isomers, more pure mixtures, or a CLA 20:80 mixture were not available for a human trial at the time of this study due to technical limitations. All preparations were stabilized with 500 ppm Tocomix L 50 (mixture of a, b, g and d tocopherols in sunflower oil, 1:1). The composition and the content of CLA isomers was shown to be stable during 24 months at 20 C. Treatments were given as softgel capsules (3 Â 2 capsules of 500 mg=day) providing a total of 1.7 g (c9,t11 þ t10,c12) CLA isomers (50:50) and 1.6 g (c9,t11 þ t10,c12) CLA isomers (80:20) per day in treatment groups for 12 weeks. Every two weeks, capsules were provided in plastic bags each containing a daily supply. Nonconsumed capsules were counted to monitor compliance. Adverse events were classified according to ICD-10 standards based on spontaneous reporting. Fatty acid composition of white blood cells was measured in 12 randomly selected subjects of each treatment at baseline and after 12 weeks. At these time points immune function parameters were measured in all subjects.
Blood sampling
Fasting blood samples were obtained on days 1 and 85 by venipuncture into vacutainers containing clot activator and gel for serum preparation, K 3 EDTA for hematology or lithium heparin for isolation of peripheral blood mononuclear cells.
Response to hepatitis B vaccination
Volunteers were vaccinated for hepatitis B (Engerix 1 -B, SmithKline Beecham) according to an accelerated schedule consisting of intramuscular injections delivering 20 mg hepatitis B antigen on days 43, 57 and 71 of the study. Serum antihepatitis B antibody titers were measured before the study and at days 71 and 85 of the study (14 days after the second and third vaccination, respectively). The concentration of hepatitis B-specific antibodies in serum was determined using a commercially available ELISA kit (Enzygnost 1 AntiHBs II test kit, Dade Behring, Marburg, Germany). The proliferative response to hepatitis B antigen was measured at day 85 as specified below.
DTH response
Delayed-type recall responses were assessed at days 01 and 85 by standardized separate intra-dermal application of seven recall-antigens (tetanus, diphteria, streptococcus (group C), tuberculin, candida (albicans), trichophyton (mentagrophytes) and Proteus (mirabilis)) using the Multitest 1 CMI (IMTIX, Pasteur Mérieux Connaught Transplantation, Amstelveen, Netherlands). Trained evaluators assessed responses after 48 AE 4 h by measuring induration diameters. Reactions ! 2 mm were used to calculate the number of positive reactions per subject per time point and the total diameter of all positive responses per subject per time point.
Isolation of peripheral blood mononuclear cells (PBMC)
PBMC were isolated on density gradients (Ficoll Paque, Pharmacia), washed twice in Earle's balanced salt solution and resuspended in RPMI-1640 medium supplemented with 10% heat inactivated autologous plasma and with glutamax, hepes (2 mM), and gentamycin (50 mg=ml, all Gibco, Paisly, UK). Suspensions containing appropriate concentrations of viable PBMC were prepared using acridine orange=ethidium bromide staining and evaluation by fluorescence microscopy.
CLA content of PBMC PBMC ( $ 4 Â 10 7 ) were resuspended in 0.5 ml MilliQ and stored below À70 C until analysis. The lipids were methylated with sodium methoxide (20 min, 50 C) to avoid isomerization of CLA isomers. Total fatty acid methylesters were analyzed using methyl heptadecanoate as internal standard as described previously by Kramer et al (1998) . Chromium released into the supernatant was determined by beta emission, using a 1450 Microbetacounter in conjunction with Optiphase Hisafe II scintilation fluid (Wallac, Turku, Finland).
Mitogen and hepatitis B antigen-induced proliferation
For phytohemagglutinin (PHA) stimulation, triplicate samples of 2 Â 10 5 viable PBMC were stimulated for 72 h with 0 and 10 mg=ml PHA (Murex, Biotech Limited, Dartford, UK) in RPMI-1640 medium with 10% heat-inactivated autologous plasma. For lipopolysaccharide (LPS), two batches with different biological activity had to be used (from E. coli B4, Sigma, St Louis, USA). Batch 1 was used at 0 and 75 mg=ml for both time points of cohort 1, batch 2 at 0 and 35 mg=ml for the other cohorts. Incubation with LPS was 120 h. For hepatitis B-specific stimulation, triplicate samples were incubated for 144 h with 0, 1.6, 3.1, 6.3 and 12.5 mg=ml hepatitis B antigen (SmithKline Beecham, Belgium). Following incubation (37 C, 5% CO 2 ) in flat-bottomed 96-well microtiter plates, samples were pulsed for 18 h with 3 H-thymidine (0.4 mCi=well, Amersham, Aylesbury, UK) and incorporated 3 H-thymidine was harvested (Tomtec Harvester 96, Orange, CT, USA) and measured using a 1450 Microbetacounter (Wallac, Turku, Finland). Stimulation Indices (SI) were calculated by dividing incorporation in stimulated cells by that in the corresponding non-stimulated cells. As the doseresponse curves for the hepatitis B-specific proliferation varied between subjects, SI were used to calculate integrated SI (ISI). The ISI is the area under the curve defined by the SI at different antigen concentrations of hepatitis B antigen and by the baseline of SI ¼ 1, which is the level of no stimulation (Leroux-Roels et al, 1994) .
Responders vs non-responders Subjects were classified as responders and non-responders for antibody production and proliferation separately. For antibody production, subjects were considered responders when titers were ! 10 IU=l as these concentrations are generally considered protective against hepatitis B infection (Banatvala et al, 2000; Leroux-Roels et al, 1994) . For proliferation, subjects were categorized as responders if their ISI was ! 21.8, which corresponds with an average SI of 3 for each concentration of the dose -response curve. This arbitrary level of 3 is frequently used as threshold for antigen-specific proliferation.
Production of cytokines and PGE 2 by PBMC Replicate samples of 2 Â 10 5 viable PBMC were stimulated for 20 h at 37 C, 5% CO 2 with 10 mg=ml PHA, or with either 35 (cohort 1) or 75 (cohorts 2 and 3) mg=ml LPS. Hereafter plates were centrifuged (5 min, 500g) and supernatants of replicate wells were pooled and stored below À70 C until further analysis. IL2, IL4 and IFN-g were measured in supernatants of PHA-stimulated PBMC, and IL1-b, IL6, TNF-a and PGE 2 in supernatants of LPS-stimulated PBMC. Cytokines and PGE 2 were analysed in duplicate using commercially available kits according to the manufacturer's instructions. Cytokines were measured using ELISAs (CLB, Amsterdam, Netherlands), PGE 2 with a radioimmunoassay (Biotrak PGE 2 assay system, Amersham Pharmacia Biotech).
Statistics
Data were analyzed by two-way analysis of variance using SAS version 6.12 (SAS institute, Cary, NC, USA), with group as factor and cohort as block. Differences compared to reference were analyzed using the Dunnet test (two-sided). Parameters that were not normally distributed were analyzed after log transformation (ie anti-hepatitis B antibody titers, ISI, SI, cytokine and PGE 2 concentrations). To this end anti hepatitis B antibody titers <1 were set at 1, ISI <10 was set at 10. Results are presented as least square means and 95% confidence intervals. Log-transformed data were transformed back to geometric means. The number of responders for hepatitis B-specific antibody production and proliferation were analyzed by Fisher's exact test.
Results
Baseline characteristics, randomization, compliance and adverse events Randomization was successful as age, BMI and total cholesterol did not differ between groups (Table 2) . Systolic and diastolic blood pressure, fasting serum lipids and the blood chemistry parameters (including liver enzymes and glucose) were within the normal range, did not differ between groups and were not affected by the intervention, apart from a slight increase in HDL cholesterol in the reference group (0.10 mmol=l), but not in CLA groups (P ¼ 0.019). 
CLA and immune function in man R Albers et al
Compliance was very high (about 99%) and did not vary between treatments. Individual compliance throughout the study ranged from 93 to 100%. No differences in adverse events were observed between the treatment groups.
CLA content of PBMC
The CLA content of PBMC on days 01 and 85 was determined in 12 randomly selected subjects from each treatment group. Total CLA concentrations as percentage of the PBMC fatty acids were not significantly different between groups at baseline (0.93, 0.95 and 0.83% for reference, CLA 50:50 and CLA 80:20, respectively), whereas at day 85 the total CLA content of PBMC was significantly higher for subjects consuming CLA 50:50 (1.26%, P ¼ 0.032) or CLA 80:20 (1.32%, P ¼ 0.022), compared with reference (0.90%).
Effect of CLA consumption on ex vivo NK cell activity NK cell activity was measured, as this is an important aspect of innate immunity. At baseline, specific lysis of 51 Cr-labeled target cells ranged from 44 to 52% in the reference, 41 -51% in the CLA 50:50 and 39 -52% in the CLA 80:20 group with effector:target ratios ranging from 25:1 to 100:1. These values ranged from 40 to 49%, 39 to 47% and 39 to 48% at day 85. Neither these values nor the change from day 1 to day 85 differed between intervention groups (data not shown).
Effect of CLA consumption on response to hepatitis B vaccination
Following vaccination for hepatitis B, both concentrations of hepatitis B specific antibodies and lymphocyte proliferation induced by hepatitis B antigen were assessed to indicate elicited humoral and cellular responses. Antibody titers to hepatitis B were 4 IU=L at inclusion and remained low at day 71, with mean serum concentrations of anti-hepatitis B antibodies of 2.4 (reference), 3.4 (CLA 50:50) and 3.2 IU=l (CLA 80:20, not shown). However, at day 85 a subset of subjects mounted a humoral and=or a cellular response to the vaccine, as indicated in Figure 2 . These responses confirm the well-known variability in individual responsiveness to hepatitis B vaccination. Subjects were therefore classified as responders and non-responders for antibody production and proliferation separately. The number of responders in CLA and immune function in man R Albers et al different groups and the mean responses are summarized in Table 3 . Neither geometric mean titers (10.7, 18.8 and 8.1 for reference, CLA 50:50 and CLA 80:20, respectively) nor the mean ISI (103, 87 and 69, respectively) differed statistically significant between the groups. However, the seroprotection rates, ie the number of subjects reaching protective antibody titers, approached statistically significant differences between the groups (P ¼ 0.09). It was almost doubled in subjects consuming CLA 50:50 (62%, eg 15=24) compared to subjects consuming the reference substance (33%, 7=21), but did not reach statistical significance (P ¼ 0.075). The seroprotection rate in subjects consuming CLA 80:20 glycerides was 36% (8=22). Subjects that responded with hepatitis B-specific lymphocyte proliferation were also more prevalent in the CLA 50:50 group; 83% (20=24) compared to reference 65% (14=21) and CLA 80:20 68% (15=22), but this was not statistically significant.
Effect of CLA consumption on in vivo DTH response Specific cellular recall responses were assessed as DTH responses to seven recall antigens at base line and at day 85. The mean total induration diameter and the mean number of positive antigens for each intervention group are given in Table 4 . There were no significant differences between the treatment groups.
Effect of CLA consumption on ex vivo PBMC function
To assess the effect of CLA consumption on PBMC function, these cells were stimulated ex vivo with the T cell mitogen PHA, or with LPS, a well-known activator of human monocytes (Table 5) . Neither proliferation nor cytokine and PGE 2 concentrations at day 85, nor changes from day 01 to day 85 (not shown) differed significantly between subjects consuming reference, CLA 50:50 or CLA 80:20. 2.4 (1.8 -3.0) 2.1 (1.5 -2.7) 2.0 (1.3 -2.6) Total diameter b (mm) day 1 7.1 (4.0 -10.3) 8.6 (5.7 -11.5) 7.7 (4.5 -10.9) day 85 10.1 (6.7 -13.5) 8.7 (5.5 -11.9) 9.1 (5.7 -12.5)
Data are geometric means (95% CI) of DTH responses assessed with CMI multitest applied on days 1 and 85; only complete data sets were used for analyses. There are no significant differences between groups neither at day 1, nor at day 85, nor for the change from day 1 to day 85. a Number of antigens causing induration with a diameter ! 2 mm. b Total diameter of all indurations with a diameter ! 2 mm combined. Data indicate geometric mean (95% CI) proliferation and of cytokine and PGE 2 concentrations in supernatants of PBMC following ex vivo stimulation with 10 mg=ml PHA or 75=35 mg=ml LPS. There are no significant differences between intervention groups neither at day 1, nor at day 85, nor for the change from day 1 to day 85. a SI stimulation index (stimulated samples=unstimulated samples).
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Discussion
The present trial provides evidence in humans that supplementation with CLA 50:50 fatty acids or CLA 80:20 glycerides results in $ 35% increased CLA levels in PBMC. Interestingly, only CLA 50:50 seemed to increase the number of subjects reaching protective antibody titers following hepatitis B vaccination. Although the overall effect did not reach statistical significance (P < 0.09), twice as many subjects were seroprotected in the CLA 50:50 group (15=24), compared to the reference group (7=21). Although this difference did not reach statistical significance (P ¼ 0.075) it is in line with the observation that the number of subjects responding with specific lymphocyte proliferation was also highest in the CLA 50:50 group. These combined observations at least suggests that CLA 50:50 may have a biologically relevant enhancing effect on the response to hepatitis B vaccination, which warrants further study. Within the supplemented group, the mean level of either antibody production or lymphocyte proliferation to hepatitis B was not increased indicating that CLA did not indiscriminately stimulate ongoing immune responses. This notion is supported by our finding that CLA consumption did not affect in vivo memory responses as measured by the DTH test, or ex vivo PHA-induced proliferation and cytokine production (IFN-g, IL2 and IL4). Likewise, CLA consumption did not affect NK cell activity or ex vivo production of pro-inflammatory cytokines (TNF-a, IL1-b and IL6) or PGE 2 by LPS-stimulated monocytes. Apparently, CLA 50:50 facilitates initiation of primary responses to the hepatitis B vaccine, without further enhancing ongoing responses or affecting DTH responses, NK cell function or production of proinflammatory cytokines by monocytes. The hepatitis B vaccination was used to mimic a primary viral infection capable of inducing both humoral and the cellular responses. Standard vaccination schedules yield protection rates of 94 -99% (Coates et al, 2001) , with lower responses in older persons (> 40 y) and segregation in slow=non-, intermediate and fast responders (Leroux-Roels et al, 1994) . Here an accelerated schedule was used to provide a suboptimal trigger to the immune system, reasoning that this would be more reflective of natural infections and would leave room for improvement of the response due to the supplementation with CLA. It is therefore not surprising that we find substantially lower response rates.
Our current findings are in line with results obtained in animal studies using mixtures comparable to our CLA 50:50. Initiation of specific adaptive responses has not been addressed in such studies, but several other indicators of adaptive immune function (ie lymphocyte proliferation and IL2 production) are typically increased by feeding these mixtures to rodents (Hayek et al, 1999) . Similar to our findings, DTH responses, NK cell activity and ex vivo production of the pro-inflammatory cytokines TNF-a and IL1-b were not affected (Turek et al, 1998; Wong et al, 1997) , although IL6 was found to be increased (Hayek et al, 1999; Turek et al, 1998a) . The lack of effects on proliferation and IL2 production is at variance with some earlier findings in mice (Hayek et al, 1999; Miller et al, 1994) ; this may relate to species differences or to the limited power to detect such changes in a heterogeneous human population. In this trial we had sufficient power to detect differences of $ 40 -70% in cytokine production with the exception of IL2 (94%) and . In pigs, CLA enhanced cellular immunity by modulating phenotype of CD8 þ cells and granzyme activity, which were not measured in this study (Bassaganya-Riera et al, 2001a,b) . Importantly, the current data and those obtained in the animal studies are consistent with stimulation of adaptive immune responses. In contrast, the only other human trial assessing effects of CLA on immune function found no effect on the response to influenza vaccination or on any of the other immune functions measured (Kelley et al, 2000 (Kelley et al, , 2001 . However, the power of that study, with only 10 subjects in the treatment group and seven in the control group, was insufficient to detect any but the most dramatic effects on immune function. Moreover, the CLA preparation used for that trial had a different composition, delivering only 573 mg=day t10,c12 CLA, 446 mg=day c9,t11 CLA and 1516 mg=day of various other CLA isomers.
The CLA 50:50 main isomers ratio (c9t11:t10,c12) used in this study (free fatty acids) is similar to most products used in previous studies. The c9,t11 CLA isomer in this material was concentrated via a food-grade process resulting in CLA glycerides with an 80:20 ratio of c9,t11 CLA:t10,c12 CLA isomers. Both preparations increased the incorporation of total CLA in PBMC by $ 35%. Moreover, the two studies that directly compared effects of CLA given as fatty acids and as glycerides found essentially identical effects on mammary cancer prevention (Ip et al, 1995) and body composition (Rahman et al, 2001) . Recently, we also obtained identical effects on body composition when feeding mice CLA 50:50 either as free fatty acid or as glycerides (unpublished data). We consider it therefore highly unlikely that the chemical form accounts for the distinct effects of CLA 50:50 fatty acids and CLA 80:20 glycerides on the response to hepatitis B vaccination. Instead, the two main CLA isomers may differ in their activity. Consumption of 846 mg=day c9,t11 CLA and 879 mg=day t10,c12 CLA in the CLA 50:50 group was effective, whereas 64% less t10,c12 CLA (319 mg=day) in combination with 46% more c9,t11 CLA (1236 mg=day) in the CLA 80:20 group was not. As intake of other CLA isomers was very low and virtually identical in both treatment groups, this suggests that t10,c12 CLA is the (most) active isomer in this study and that c9,t11 CLA is substantially less effective or ineffective. Such selective activity of t10,c12 CLA on immune function is in line with the observation that feeding t10,c12 CLA, but not c9,t11 CLA, increased lymphocyte proliferation in mice (DeVoney et al, 1999) .
It has been postulated that some of the physiological effects of CLA, particularly of the t10,c12 CLA isomer, may be explained by modulation of eicosanoid production from linoleic acid and=or production of biochemically distinct CLA and immune function in man R Albers et al CLA-derived eicosanoids Sebedio et al, 1997) . However, the data on effects of CLA on PGE 2 production seem inconsistent, as several studies have shown inhibition of PGE 2 production in vitro (Liu & Belury, 1998; Miller et al, 2001 ) and in CLA-supplemented rats Sugano et al, 1997 Sugano et al, , 1998 and guinea pigs (Whigham et al, 2001 (Whigham et al, , 2002 . Other studies are in line with our current finding as they found no significant reduction of PGE 2 production in humans (Kelley et al, 2001 ), mice (Hayek et al, 1999) and rats (Turek et al, 1998) . It has also been suggested that CLA may exert some of its biological effects via interaction with PPARa (Moya-Camarena et al, 1999) and PPARg (Houseknecht et al, 1998) . These receptors are widely expressed in the immune system and are involved in regulating expression of various genes involved in important immune functions such as proliferation, apoptosis and inflammation. However, whether eicosanoid metabolism and=or PPAR activation are actually involved in the immunomodulatory activity of CLA remains to be established, also because recent studies suggest that effects of t10,c12 CLA on body composition and target gene expression may not require elongation=desaturation or expression of PPARa (Peters et al, 2001) .
Taken together, our results suggest that supplementation of healthy males with CLA 50:50 may improve the ability of their immune system to mount a protective adaptive response to 'new' infections as witnessed by the increased seroprotection rate following hepatitis B vaccination. As CLA was found to double the number of subjects mounting a protective response without further stimulating ongoing responses, CLA supplementation may be particularly beneficial for those individuals who for some reason are slow or low responders to the vaccination. However, these effects need to be confirmed and it also remains to be established whether similar benefits can be achieved after exposure to naturally occurring infections. If so, CLA supplementation could tentatively contribute to countering some of the deleterious effects of declined immune function due to stress, exercise and=or aging. This hypothesis warrants testing in larger scale longer-term intervention trials, preferably assessing incidence and severity of naturally occurring infections.
